These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 28988229)

  • 1. Studying Kidney Disease Using Tissue and Genome Engineering in Human Pluripotent Stem Cells.
    Garreta E; González F; Montserrat N
    Nephron; 2018; 138(1):48-59. PubMed ID: 28988229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of kidney organoids derived from human pluripotent stem cells.
    Kim YK; Nam SA; Yang CW
    Korean J Intern Med; 2018 Jul; 33(4):649-659. PubMed ID: 29961307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 genome editing in human pluripotent stem cells: Harnessing human genetics in a dish.
    González F
    Dev Dyn; 2016 Jul; 245(7):788-806. PubMed ID: 27145095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids.
    Hendriks D; Clevers H; Artegiani B
    Cell Stem Cell; 2020 Nov; 27(5):705-731. PubMed ID: 33157047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient CRISPR/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells.
    Kime C; Mandegar MA; Srivastava D; Yamanaka S; Conklin BR; Rand TA
    Curr Protoc Hum Genet; 2016 Jan; 88():21.4.1-21.4.23. PubMed ID: 26724721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene editing of stem cells for kidney disease modelling and therapeutic intervention.
    Lau RW; Wang B; Ricardo SD
    Nephrology (Carlton); 2018 Nov; 23(11):981-990. PubMed ID: 29851168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS disease models with human pluripotent stem cells in the CRISPR age.
    Muffat J; Li Y; Jaenisch R
    Curr Opin Cell Biol; 2016 Dec; 43():96-103. PubMed ID: 27768957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TALEN- and CRISPR/Cas9-Mediated Gene Editing in Human Pluripotent Stem Cells Using Lipid-Based Transfection.
    Hendriks WT; Jiang X; Daheron L; Cowan CA
    Curr Protoc Stem Cell Biol; 2015 Aug; 34():5B.3.1-5B.3.25. PubMed ID: 26237572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.
    Lotfi M; Morshedi Rad D; Mashhadi SS; Ashouri A; Mojarrad M; Mozaffari-Jovin S; Farrokhi S; Hashemi M; Lotfi M; Ebrahimi Warkiani M; Abbaszadegan MR
    Stem Cell Rev Rep; 2023 Nov; 19(8):2576-2596. PubMed ID: 37723364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CRISPR/Cas system for genome editing in pluripotent stem cells].
    Vasil'eva EA; Melino D; Barlev NA
    Tsitologiia; 2015; 57(1):19-30. PubMed ID: 25872372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids.
    Freedman BS; Brooks CR; Lam AQ; Fu H; Morizane R; Agrawal V; Saad AF; Li MK; Hughes MR; Werff RV; Peters DT; Lu J; Baccei A; Siedlecki AM; Valerius MT; Musunuru K; McNagny KM; Steinman TI; Zhou J; Lerou PH; Bonventre JV
    Nat Commun; 2015 Oct; 6():8715. PubMed ID: 26493500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney Organoids: A Translational Journey.
    Morizane R; Bonventre JV
    Trends Mol Med; 2017 Mar; 23(3):246-263. PubMed ID: 28188103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.
    Chaterji S; Ahn EH; Kim DH
    Theranostics; 2017; 7(18):4445-4469. PubMed ID: 29158838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR Gene Editing in the Kidney.
    Cruz NM; Freedman BS
    Am J Kidney Dis; 2018 Jun; 71(6):874-883. PubMed ID: 29606501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA fragment editing of genomes by CRISPR/Cas9.
    Li JH; Shou J; Wu Q
    Yi Chuan; 2015 Oct; 37(10):992-1002. PubMed ID: 26496751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of genome-edited pluripotent stem cells and mice by CRISPR/Cas.
    Horii T; Hatada I
    Endocr J; 2016; 63(3):213-9. PubMed ID: 26743444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing kidney development and disease using kidney organoids and CRISPR engineering.
    Safi W; Marco A; Moya D; Prado P; Garreta E; Montserrat N
    Front Cell Dev Biol; 2022; 10():948395. PubMed ID: 36120564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome Engineering for Stem Cell Transplantation.
    Argani H
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.